During the last session, Bluejay Diagnostics Inc (NASDAQ:BJDX)’s traded shares were 0.2 million, with the beta value of the company hitting 0.51. At the end of the trading day, the stock’s price was $1.98, reflecting an intraday loss of -10.41% or -$0.23. The 52-week high for the BJDX share is $316.92, that puts it down -15906.06 from that peak though still a striking -9.09% loss since the share price plummeted to a 52-week low of $2.16. The company’s market capitalization is $1.09M, and the average intraday trading volume over the past 10 days was 6.74 million shares, and the average trade volume was 1.13 million shares over the past three months.
Bluejay Diagnostics Inc (BJDX) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 3.00. BJDX has a Sell rating from 0 analyst(s) out of 1 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 1 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be 0.
Bluejay Diagnostics Inc (NASDAQ:BJDX) trade information
Bluejay Diagnostics Inc (BJDX) registered a -10.41% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -10.41% in intraday trading to $1.98, hitting a weekly high. The stock’s 5-day price performance is -23.26%, and it has moved by -51.71% in 30 days. Based on these gigs, the overall price performance for the year is -99.10%. The short interest in Bluejay Diagnostics Inc (NASDAQ:BJDX) is 22762.0 shares and it means that shorts have 0.54 day(s) to cover.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 26.06%.
BJDX Dividends
Bluejay Diagnostics Inc is due to release its next quarterly earnings on 2024-Mar-27. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Bluejay Diagnostics Inc (NASDAQ:BJDX)’s Major holders
Bluejay Diagnostics Inc insiders own 0.31% of total outstanding shares while institutional holders control 3.00%, with the float percentage being 3.01%.
